期刊文献+

肝硬化腹腔积液并发肝肾综合征的高危因素探讨 被引量:6

原文传递
导出
摘要 目的探讨肝硬化腹腔积液患者并发肝肾综合征(HRS)的高危因素。方法随机选择肝硬化腹腔积液患者117例,其中并发肝肾综合征组(HRS组)57例,未并发HRS组(非HRS组)60例。统计年龄、性别、肝硬化其他并发症、肝脏生化、腹腔积液检查结果等指标,并进行统计学分析。结果肝性脑病、原发性细菌性腹膜炎、外周血白细胞数、凝血酶原活动度、血清总胆红素、血清白蛋白、血清钠、腹腔积液白细胞数等与肝硬化腹腔积液并发HRS患者密切相关(P〈0.05)。结论肝脏储备功能、肝性脑病、原发性细菌性腹膜炎、低钠血症作为HRS的易患因素可以预测HRS的发生,因此预防并积极治疗这些危险因素对改善患者预后有重要意义。
出处 《中国综合临床》 北大核心 2007年第6期508-510,共3页 Clinical Medicine of China
  • 相关文献

参考文献4

  • 1徐学康.肝脏病继发肾损害[M]//钱桐荪.3版.肾脏病学.北京:华夏出版社,2001:477.
  • 2Arroyio V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis[J]. Hepatology, 1996,23 ( 1 ) : 164-166.
  • 3赵守松.肝肾综合征的研究现状[J].实用肝脏病杂志,2006,9(1):58-61. 被引量:5
  • 4Guevara M. Treatment of hepatorenal syndrome[J]. J Gastroenterol Hepatol,2003,26 (2):270-274.

二级参考文献18

  • 1Aguillon D,Seguin P, Maledant Y. Hepatorenal syndrome: from physiopathology to treatment. Ann Fr Anesth Reanim, 2003,22 ( 1 ):30-8.
  • 2Bataller R, Gines P, Arroyo V, et al. Hepatorenal syndrome. Clin Liver Dis, 2002,4920:487 - 507.
  • 3Anand A, Harry D, Holt S, et al. Endothelin is an important of renal function in a rat model of acute liver and renal failure. Gut, 2002,50:111-117.
  • 4Moller S, Emmehlth C, Henriksen JH. Elevated circulating plasma endothelin- 1 concentrations in cirrhosis. J Hepatol, 1993, 19:285-290.
  • 5Bardi A, Sapunar J, Oksexlirerg D, et al. Intrarenal arterial Doppler ultrasonography in cirrhosis patients with aseites, with and without hepatorenal syndrome. Rev Med Chil, 2002, 130: 173 - 180.
  • 6Saner FH, Fruhauf NR,Schafers RF, et al. Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome. Eur J Gaslroenterol Hepatol, 2003 Aug, 15 (8) : 925 - 7.
  • 7Solanki P, Chawla A, Garg R, et al, Beneficial effects of terlipressin in hepalorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol, 2003,18 : 152-156.
  • 8Di Campli C, Zileri Dal Verme L, Andrisani MC, et al. Advances in extracolporeal detoxification by MARS dialysis in patients with liver failure. Curr Med Chem, 2003,10(4) : 341 - 8.
  • 9Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal synthrome with extracorporeal albumin dialysis MARS: results of a ptvspective, randomized, controlled clinical trial. Liver Transpl,2000,6 : 277 - 286.
  • 10Gonwa TA, Klintmalm GB, Levy M, et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation, 1995,59 : 361-365.

共引文献4

同被引文献45

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部